Yi Jer Tan
Impact in
- Cancer Research top 10%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Histone Deacetylase Inhibitors Research 4
- Oncology 6
- Cancer-related Molecular Pathways 3
- PARP inhibition in cancer therapy 3
- Co-authors
- Chern Ein Oon (10 shared papers)Yeuan Ting Lee (9 shared papers)Xiaonan Liang (1 shared paper)Chenyang Li (1 shared paper)Xiaolan Zhang (1 shared paper)Jia Song (1 shared paper)Feng Cui (3 shared papers)Chuanling Qiao (3 shared papers)
In The Last Decade
Yi Jer Tan
23 papers receiving 1.5k citations
Yi Jer Tan's Hit Papers
Peers
Comparison fields: 5 of 109
- Cancer Research 227
- Oncology 355
- Geriatrics and Gerontology 36
- Molecular Biology 651
- Immunology 163
Countries citing papers authored by Yi Jer Tan
This map shows the geographic impact of Yi Jer Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi Jer Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi Jer Tan more than expected).
Fields of papers citing papers by Yi Jer Tan
This network shows the impact of papers produced by Yi Jer Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi Jer Tan. The network helps show where Yi Jer Tan may publish in the future.
Co-authors
The 25 scholars most cited alongside Yi Jer Tan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Molecular targeted therapy: Treating cancer with specificity Hit paper breakdown → | 2018 | 833 |
| 2 | Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine Hit paper breakdown → | 2022 | 164 |
| 3 | 2021 | 132 | |
| 4 | 2010 | 57 | |
| 5 | 2014 | 44 | |
| 6 | 2020 | 37 | |
| 7 | 2007 | 37 | |
| 8 | 2018 | 33 | |
| 9 | 2019 | 24 | |
| 10 | 2007 | 21 | |
| 11 | 2019 | 18 | |
| 12 | 2007 | 18 | |
| 13 | 2017 | 15 | |
| 14 | 2014 | 12 | |
| 15 | 2022 | 12 | |
| 16 | 2021 | 8 | |
| 17 | 2024 | 8 | |
| 18 | 2013 | 8 | |
| 19 | [Development of human myeloid leukemia-like phenotype in NUP98-PMX1 transgenic mice]. | 2004 | 5 |
| 20 | 2022 | 4 |
About Yi Jer Tan
Yi Jer Tan is a scholar working on Molecular Biology, Oncology, Geriatrics and Gerontology, Epidemiology and Immunology, having authored 25 papers that have together received 1.5k indexed citations. Recurring topics across this work include Sirtuins and Resveratrol in Medicine (5 papers), Histone Deacetylase Inhibitors Research (4 papers), Insect Pest Control Strategies (3 papers), Cancer-related Molecular Pathways (3 papers), PARP inhibition in cancer therapy (3 papers), Cholinesterase and Neurodegenerative Diseases (2 papers), Computational Drug Discovery Methods (2 papers) and Immune Cell Function and Interaction (2 papers). The work is most often cited by research in Cancer Research (227 citations), Oncology (355 citations), Geriatrics and Gerontology (36 citations), Molecular Biology (651 citations) and Immunology (163 citations). Yi Jer Tan has collaborated with scholars based in China, Malaysia and Australia. Frequent co-authors include Chern Ein Oon, Yeuan Ting Lee, Xiaonan Liang, Chenyang Li, Xiaolan Zhang, Jia Song, Feng Cui, Chuanling Qiao, Shengdian Wang and Marco Falasca. Their work appears in journals such as Journal of Medical Entomology, International Journal of Infectious Diseases, Therapeutic Advances in Medical Oncology, The Journal of Immunology and Stem Cell Research & Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.